May 4th 2026

PRESS RELEASE

Vabilo medijem: Sestanek mednarodnega konzorcija IFIGENEIA

Ljubljana, 4. maj 2026: V Sloveniji trenutno poteka razvoj, ki odpira širše vprašanje evropske odvisnosti pri zdravljenju raka in drugih bolezni z radioizotopi.

V okviru projekta IFIGENEIA se razvija tehnologija za generiranje medicinskih radioizotopov – ključnih za diagnostiko in zdravljenje, pri katerih je Evropa še vedno v veliki meri odvisna od uvoza.

Po ocenah se v Evropi vsako leto opravi več kot 10 milijonov postopkov z uporabo radioizotopov, pri čemer motnje v dobavi vplivajo na dostopnost zdravljenja. Vprašanje zanesljive oskrbe zato postaja tudi strateško in ne le zdravstveno.

Ob srečanju mednarodnih strokovnjakov bo v četrtek, 7. maja omogočen dostop do strokovnjakov mednarodnega konzorcija. Za izjave so na voljo domači in tuji sogovorniki.

Možne teme:

- ali lahko Evropa postane bolj neodvisna pri oskrbi z radioizotopi
- kakšen je dejanski vpliv na bolnike v Sloveniji
- kakšno vlogo lahko pri tem odigra domače znanje

Če bi vas tema zanimala, z veseljem posredujem dodatne informacije ali uredim obisk.

Lep pozdrav,
Tonja Blatnik
041 391 161

Več informacij

- Aristotle University of Thessaloniki, Grčija,

Prof Dimitrios Sampsonidis, koordinator projekta IFIGENEIA

- Institut »Jožef Stefan«, Slovenija,

Urška Mrgole, urska.mrgole(at)ijs.si, Vodja komunikacije in diseminacije projekta IFIGENEIA

O projektu (v angleščini)

The IFIGENEIA Project aspires to introduce, develop and deliver the complete design study and the precise business plan for the implementation of the LINear ACcelerator (LINAC) technology in radiation therapy, diagnostic and theragnostic (a treatment that combines therapeutics with diagnostics) procedures in Europe. The objective of the IFIGENEIA project is to create the complete design and implementation study for a cutting-edge LINAC facility in the Balkans. This will be achieved by establishing Excellence Hubs in Greece, Slovenia, and Cyprus. These hubs will be dedicated to developing and implementing a LINAC-based facility capable of producing a diverse range of marketable radioisotopes for medical, industrial, and research applications. LINAC technologies offer a unique, compact, cost-effective, and environmentally friendly solution for sustainable production, management, accessibility, and promotion of nuclear medicine and molecular imaging technologies. Unlike current radioisotope production methods, mostly reliant on older nuclear reactors using highly enriched uranium with associated concerns about global availability, safety, and environmental issues, or on cyclotrons limited to a narrow range of radioisotopes, LINACs enable the production of a broader range due to their tunability in energy, targets, and currents.

Partnerji

Funded by the European Union

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. Grant Agreement No: 101186921.